1 February 2024 Ankylosing Spondylitis NSAIDS Does added NSAID reduce radiographic progression in axSpA?
8 December 2022 Ankylosing Spondylitis Biosimilars Scleroderma Spondyloarthritis Good news: you’re trusted
17 March 2022 Ankylosing Spondylitis Biologics Pharmacy Guild of Australia Mavrilimumab opens up GCA promise
10 March 2022 Ankylosing Spondylitis Gout Juvenile Arthritis Pharmacy Guild of Australia Ross River Virus Promising findings on steroid-sparing options for PMR and GCA
10 March 2022 Ankylosing Spondylitis osteomyelitis Scleroderma The needle moves on adding more to MTX in PsA
24 February 2022 Ankylosing Spondylitis Biologics Polymyalgia Rheumatica Rheumatoid Arthritis Spondyloarthritis Why men won’t take allopurinol
9 November 2021 Ankylosing Spondylitis Biologics Gout Pharmacy Guild of Australia What’s on the way for GCA?
21 October 2021 Ankylosing Spondylitis Biologics Biosimilars Conditions O&G How to help patients understand their biosimilar options
7 October 2021 Ankylosing Spondylitis Biologics Corticosteroids COVID-19 No significant link between cancer and bDMARDs
1 July 2021 Ankylosing Spondylitis Biologics PBS Scleroderma Guselkumab now PBS-listed for psoriatic arthritis
29 April 2021 Ankylosing Spondylitis Biologics Scleroderma Bimekizumab takes on all-comers in psoriasis – and wins
25 March 2021 Ankylosing Spondylitis Biologics Conditions Scleroderma Considering Taltz withdrawal in PsA patients?
18 March 2021 Ankylosing Spondylitis Biologics Cognitive Therapies FDA approves Actemra for scleroderma lung
